{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:31:57Z","timestamp":1785353517813,"version":"3.55.0"},"reference-count":80,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Lefamulin, a new, first-in-class pleuromutilin antibiotic, was recently approved by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of patients with community-acquired bacterial pneumonia (CABP). In this context, this review aimed to evaluate its activity against the most common pathogens causing this infection. A thorough search was performed in five databases (Embase, Scopus, Web of Science, PubMed, PubMed Central) from their inception to 14th of October 2025. Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) resistance breakpoints were applied. Out of a total of 224 articles identified, 11 were deemed eligible for inclusion. Resistance among Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus isolates was 0\u20132.6%, 0\u20132.4%, and 0\u20134.3%, respectively. Even among isolates with specific mechanisms of resistance, such as \u03b2-lactamase-producing H. influenzae and methicillin-resistant S. aureus, resistance was below 2.4% and 3.4%, respectively. Among isolates for which no breakpoints were available (Moraxella catarrhalis, atypical pathogens, Enterococcus spp., Streptococcus spp., Haemophilus spp., and Staphylococcus spp.), MIC90 values were low. An exception were isolates belonging to Enterococcus spp., which displayed MIC90 values ranging from 0.25 to &gt;16 mg\/L in the two studies with relevant data. Lefamulin demonstrated broad in vitro activity against key pathogens causing CABP, making it a considerable addition to the therapeutic options for such infections, especially in cases where first-line agents cannot be used for reasons such as allergy or previous failure.<\/jats:p>","DOI":"10.3390\/antibiotics15010058","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T13:35:47Z","timestamp":1767620147000},"page":"58","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Resistance to Lefamulin: An Evaluation of Data from In Vitro Antimicrobial Susceptibility Studies"],"prefix":"10.3390","volume":"15","author":[{"given":"Matthew E.","family":"Falagas","sequence":"first","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 151 23 Athens, Greece"},{"name":"Department of Medicine, School of Medicine, European University Cyprus, Nicosia 1516, Cyprus"},{"name":"Department of Medicine, School of Medicine, Tufts University, Boston 02111, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Fanariotis","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 151 23 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura T.","family":"Romanos","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 151 23 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos M.","family":"Katsikas","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 151 23 Athens, Greece"},{"name":"Department of Medicine, Hygeia Hospital, 151 23 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos A.","family":"Kakoullis","sequence":"additional","affiliation":[{"name":"Department of Medicine, School of Medicine, European University Cyprus, Nicosia 1516, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMra1312885","article-title":"Community-Acquired Pneumonia","volume":"371","author":"Musher","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_2","unstructured":"(2024). GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global, Regional, and National Incidence and Mortality Burden of Non-COVID-19 Lower Respiratory Infections and Aetiologies, 1990\u20132021: A Systematic Analysis from the Global Burden of Disease Study 2021. Lancet Infect. Dis., 24, 974\u20131002."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/thoraxjnl-2013-204282","article-title":"Risk Factors for Community-Acquired Pneumonia in Adults in Europe: A Literature Review","volume":"68","author":"Torres","year":"2013","journal-title":"Thorax"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1001\/jama.2024.14796","article-title":"Community-Acquired Pneumonia: A Review","volume":"332","author":"Vaughn","year":"2024","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1007\/s15010-024-02314-w","article-title":"Epidemiology and Risk Factors of Community-Acquired Pneumonia in Patients with Different Causes of Immunosuppression","volume":"52","author":"Reichel","year":"2024","journal-title":"Infection"},{"key":"ref_6","unstructured":"McDermott, K.W., and Roemer, M. (2006). Most Frequent Principal Diagnoses for Inpatient Stays in U.S. Hospitals, 2018. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs, Agency for Healthcare Research and Quality (US)."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jinf.2010.07.015","article-title":"Study of Community-Acquired Pneumonia: Incidence, Patterns of Care, and Outcomes in Primary and Hospital Care","volume":"61","author":"Capelastegui","year":"2010","journal-title":"J. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Theilacker, C., Sprenger, R., Leverkus, F., Walker, J., H\u00e4ckl, D., von Eiff, C., and Schiffner-Rohe, J. (2021). Population-Based Incidence and Mortality of Community-Acquired Pneumonia in Germany. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0253118"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0140-6736(15)60733-4","article-title":"Community-Acquired Pneumonia","volume":"386","author":"Prina","year":"2015","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults","volume":"373","author":"Jain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e0001522","DOI":"10.1128\/cmr.00015-22","article-title":"The Microbial Etiology of Community-Acquired Pneumonia in Adults: From Classical Bacteriology to Host Transcriptional Signatures","volume":"35","author":"Gadsby","year":"2022","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_13","unstructured":"(2025, October 29). The Aetiology and Antibiotic Management of Community-Acquired Pneumonia in Adults in Europe: A Literature Review\u2014PubMed, Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/24532008\/."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Holter, J.C., M\u00fcller, F., Bj\u00f8rang, O., Samdal, H.H., Marthinsen, J.B., Jenum, P.A., Ueland, T., Fr\u00f8land, S.S., Aukrust, P., and Husebye, E. (2015). Etiology of Community-Acquired Pneumonia and Diagnostic Yields of Microbiological Methods: A 3-Year Prospective Study in Norway. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-0803-5"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Candel, F.J., Salavert, M., Basaras, M., Borges, M., Cant\u00f3n, R., Cercenado, E., Cilloniz, C., Estella, \u00c1., Garc\u00eda-Lechuz, J.M., and Garnacho Montero, J. (2023). Ten Issues for Updating in Community-Acquired Pneumonia: An Expert Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12216864"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0040-1709992","article-title":"Staphylococcus aureus Pneumonia in the Community","volume":"41","author":"He","year":"2020","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Waagsb\u00f8, B., Tranung, M., Dam\u00e5s, J.K., and Heggelund, L. (2022). Antimicrobial Therapy of Community-Acquired Pneumonia during Stewardship Efforts and a Coronavirus Pandemic: An Observational Study. BMC Pulm. Med., 22.","DOI":"10.1186\/s12890-022-02178-6"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Cill\u00f3niz, C., Garcia-Vidal, C., Ceccato, A., and Torres, A. (2018). Antimicrobial Resistance Among Streptococcus pneumoniae. Antimicrobial Resistance in the 21st Century, Springer.","DOI":"10.1007\/978-3-319-78538-7_2"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sfeir, M.M. (2025). Haemophilus Influenzae Global Epidemiology and Antimicrobial Susceptibility Patterns Including Ampicillin and Amoxicillin-Clavulanate Resistance Based on \u03b2-Lactamase Production, 2013\u20132022. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-025-11438-9"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/cid\/ciw300","article-title":"Staphylococcus aureus Community-Acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes","volume":"63","author":"Self","year":"2016","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMcp2303286","article-title":"Community-Acquired Pneumonia","volume":"389","author":"File","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.2147\/IDR.S540124","article-title":"Efficacy of Lefamulin for Community-Acquired Bacterial Pneumonia (CABP) Patients: Pooled Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 1, LEAP 2 and LEAP China Trials","volume":"18","author":"Liang","year":"2025","journal-title":"Infect. Drug Resist."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Zahari, N.I.N., Engku Abd Rahman, E.N.S., Irekeola, A.A., Ahmed, N., Rabaan, A.A., Alotaibi, J., Alqahtani, S.A., Halawi, M.Y., Alamri, I.A., and Almogbel, M.S. (2023). A Review of the Resistance Mechanisms for \u03b2-Lactams, Macrolides and Fluoroquinolones among Streptococcus pneumoniae. Medicina, 59.","DOI":"10.3390\/medicina59111927"},{"key":"ref_24","unstructured":"(2025, November 25). No Development of Ciprofloxacin Resistance in the Haemophilus Species Associated with Pneumonia over a 10-Year Study | BMC Infectious Diseases. Available online: https:\/\/link.springer.com\/article\/10.1186\/s12879-015-1267-3."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2147\/IDR.S84209","article-title":"Prevalence and Resistance Pattern of Moraxella Catarrhalis in Community-Acquired Lower Respiratory Tract Infections","volume":"8","author":"Shaikh","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/jac\/dkac170","article-title":"Global Prevalence of Resistance to Macrolides in Mycoplasma pneumoniae: A Systematic Review and Meta-Analysis","volume":"77","author":"Wang","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1093\/jac\/dkz084","article-title":"Introduction: Lefamulin and Pharmacokinetic\/Pharmacodynamic Rationale to Support the Dose Selection of Lefamulin","volume":"74","author":"Rodvold","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/joim.13378","article-title":"Clinical Use of Lefamulin: A First-in-class Semisynthetic Pleuromutilin Antibiotic","volume":"291","author":"Covvey","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s40495-022-00297-6","article-title":"Lefamulin: A New Hope in the Field of Community-Acquired Bacterial Pneumonia","volume":"8","author":"Adhikary","year":"2022","journal-title":"Curr. Pharmacol. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/phar.2166","article-title":"Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic","volume":"38","author":"Veve","year":"2018","journal-title":"Pharmacotherapy"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1093\/cid\/ciaa336","article-title":"Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-Acquired Bacterial Pneumonia","volume":"71","author":"Watkins","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"39004","DOI":"10.1038\/srep39004","article-title":"A Novel Pleuromutilin Antibacterial Compound, Its Binding Mode and Selectivity Mechanism","volume":"6","author":"Eyal","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1177\/0018578719897071","article-title":"Lefamulin","volume":"57","author":"Kozhokar","year":"2022","journal-title":"Hosp. Pharm."},{"key":"ref_34","unstructured":"U.S. Food and Drug Administration (2025, October 30). XENLETA (Lefamulin) Injection, for Intravenous Use XENLETA (Lefamulin) Tablets, for Oral Use, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/211672s000,211673s000lbl.pdf."},{"key":"ref_35","unstructured":"European Medicines Agency (2018). Xenleta (Lefamulin): Annex I Summary of Product Characteristics (English), European Medicines Agency. Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2022\/20220708156315\/anx_156315_en.pdf."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Wu, S., Zheng, Y., Guo, Y., Yin, D., Zhu, D., and Hu, F. (2020). In Vitro Activity of Lefamulin Against the Common Respiratory Pathogens Isolated From Mainland China During 2017\u20132019. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.578824"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e02008-16","DOI":"10.1128\/AAC.02008-16","article-title":"In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China","volume":"61","author":"Waites","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","first-page":"149","article-title":"In Vitro Susceptibility of Common Bacterial Pathogens Causing Respiratory Tract Infections in Canada to Lefamulin, a New Pleuromutilin","volume":"6","author":"Taylor","year":"2021","journal-title":"J. Assoc. Med. Microbiol. Infect. Dis. Can."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1128\/AAC.05789-11","article-title":"Antimicrobial Activity of the Investigational Pleuromutilin Compound BC-3781 Tested against Gram-Positive Organisms Commonly Associated with Acute Bacterial Skin and Skin Structure Infections","volume":"56","author":"Sader","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/jac\/dks001","article-title":"Antimicrobial Activity of the Novel Pleuromutilin Antibiotic BC-3781 against Organisms Responsible for Community-Acquired Respiratory Tract Infections (CARTIs)","volume":"67","author":"Sader","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1128\/AAC.00358-13","article-title":"Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010","volume":"57","author":"Paukner","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/jac\/dkad389","article-title":"7-Year (2015\u201321) Longitudinal Surveillance of Lefamulin in Vitro Activity against Bacterial Pathogens Collected Worldwide from Patients with Respiratory Tract Infections Including Pneumonia and Characterization of Resistance Mechanisms","volume":"79","author":"Paukner","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e02161-18","DOI":"10.1128\/AAC.02161-18","article-title":"Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015\u20132016)","volume":"63","author":"Paukner","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e02158-18","DOI":"10.1128\/AAC.02158-18","article-title":"Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015\u20132016 and Characterization of Resistance Mechanisms","volume":"63","author":"Mendes","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1128\/AAC.00627-16","article-title":"In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States","volume":"60","author":"Mendes","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s10096-025-05175-9","article-title":"Antimicrobial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Pneumonia: Results from the China Antimicrobial Surveillance Network in 2020\u20132022","volume":"44","author":"Ding","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1093\/jac\/dkv107","article-title":"Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007\u20132013","volume":"70","author":"Golden","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_48","unstructured":"Clinical and Laboratory Standards Institute (2024). Performance Standards for Antimicrobial Susceptibility Testing, Clinical and Laboratory Standards Institute. Available online: https:\/\/clsi.org\/shop\/standards\/m100\/."},{"key":"ref_49","unstructured":"EUCAST (2025, October 14). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 15.0. Available online: https:\/\/www.eucast.org\/bacteria\/clinical-breakpoints-and-interpretation\/clinical-breakpoint-tables\/."},{"key":"ref_50","unstructured":"EUCAST (2025, October 14). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 8.0. European Committee on Antimicrobial Susceptibility Testing: V\u00e4xj\u00f6, Sweden, 2018. Available online: https:\/\/www.eucast.org\/bacteria\/clinical-breakpoints-and-interpretation\/clinical-breakpoint-tables\/."},{"key":"ref_51","unstructured":"EUCAST (2025, October 14). Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 1.3, January 2011. Available online: https:\/\/www.eucast.org\/bacteria\/clinical-breakpoints-and-interpretation\/clinical-breakpoint-tables\/."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"a027110","DOI":"10.1101\/cshperspect.a027110","article-title":"Pleuromutilins: Potent Drugs for Resistant Bugs\u2014Mode of Action and Resistance","volume":"7","author":"Paukner","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"File, T.M., Alexander, E., Goldberg, L., Das, A.F., Sandrock, C., Paukner, S., and Moran, G.J. (2021). Lefamulin Efficacy and Safety in a Pooled Phase 3 Clinical Trial Population with Community-Acquired Bacterial Pneumonia and Common Clinical Comorbidities. BMC Pulm. Med., 21.","DOI":"10.1186\/s12890-021-01472-z"},{"key":"ref_54","unstructured":"Nabriva Therapeutics AG (2025, October 28). A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (with or Without Adjunctive Linezolid) in Adults with Community-Acquired Bacterial Pneumonia, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02559310."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/cid\/ciz090","article-title":"Efficacy and Safety of Intravenous-to-Oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-Acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial","volume":"69","author":"File","year":"2019","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_56","unstructured":"Nabriva Therapeutics AG (2025, October 28). A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC 3781) Versus Oral Moxifloxacin in Adults with Community-Acquired Bacterial Pneumonia, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT02813694."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/jama.2019.15468","article-title":"Oral Lefamulin vs. Moxifloxacin for Early Clinical Response Among Adults with Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial","volume":"322","author":"Alexander","year":"2019","journal-title":"JAMA"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Paukner, S., Mariano, D., Das, A.F., Moran, G.J., Sandrock, C., Waites, K.B., and File, T.M. (2021). Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials. Antibiotics, 10.","DOI":"10.3390\/antibiotics10121489"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e12845","DOI":"10.1111\/eci.12845","article-title":"The Dilemma of Monotherapy or Combination Therapy in Community-Acquired Pneumonia","volume":"47","author":"Vardakas","year":"2017","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00134-023-07033-8","article-title":"ERS\/ESICM\/ESCMID\/ALAT Guidelines for the Management of Severe Community-Acquired Pneumonia","volume":"49","author":"Torres","year":"2023","journal-title":"Intensive Care Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1503\/cmaj.080358","article-title":"Respiratory Fluoroquinolones for the Treatment of Community-Acquired Pneumonia: A Meta-Analysis of Randomized Controlled Trials","volume":"179","author":"Vardakas","year":"2008","journal-title":"CMAJ Can. Med. Assoc. J."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.arbres.2022.08.012","article-title":"Validation of IDSA\/ATS Guidelines for ICU Admission in Adults over 80 Years Old with Community-Acquired Pneumonia","volume":"59","author":"Cilloniz","year":"2023","journal-title":"Arch. Bronconeumol."},{"key":"ref_63","first-page":"234","article-title":"Fluoroquinolones or Macrolides in Combination with \u03b2-Lactams in Adult Patients Hospitalized with Community Acquired Pneumonia: A Systematic Review and Meta-Analysis","volume":"23","author":"Vardakas","year":"2017","journal-title":"Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1080\/23744235.2025.2527691","article-title":"Tailoring ATS\/IDSA Community-Acquired Pneumonia Guidelines to High-Resistance Settings: An Antibiotic Stewardship Framework from Lebanon","volume":"57","author":"Attieh","year":"2025","journal-title":"Infect. Dis. Lond. Engl."},{"key":"ref_65","first-page":"101161","article-title":"Update of Guidelines for Management of Community Acquired Pneumonia in Adults by the French Infectious Disease Society (SPILF) and the French-Speaking Society of Respiratory Diseases (SPLF): Endorsed by the French Intensive Care Society (SRLF), the French Microbiology Society (SFM), the French Radiology Society (SFR) and the French Emergency Society (SFMU)","volume":"87","author":"Dinh","year":"2025","journal-title":"Respir. Med. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1097\/MJT.0000000000000551","article-title":"Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications","volume":"24","author":"Cherazard","year":"2017","journal-title":"Am. J. Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"ofad098","DOI":"10.1093\/ofid\/ofad098","article-title":"Trends in Streptococcus pneumoniae Antimicrobial Resistance in US Children: A Multicenter Evaluation","volume":"10","author":"Mohanty","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Ahmad, I., Kubaev, A., Zwamel, A.H., R., R., Baldaniya, L., kaur, J., Rani, B., and Beig, M. (2025). Insights into Haemophilus Macrolide Resistance: A Comprehensive Systematic Review and Meta-Analysis. PLoS Negl. Trop. Dis., 19.","DOI":"10.1371\/journal.pntd.0012878"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Abavisani, M., Keikha, M., and Karbalaei, M. (2024). First Global Report about the Prevalence of Multi-Drug Resistant Haemophilus Influenzae: A Systematic Review and Meta-Analysis. BMC Infect. Dis., 24.","DOI":"10.1186\/s12879-023-08930-5"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5069","DOI":"10.2147\/IDR.S374805","article-title":"Antimicrobial Resistance Trends of the Most Common Causative Pathogens Associated with Community-Acquired Respiratory Infections in China: 2009\u20132018","volume":"15","author":"Zhao","year":"2022","journal-title":"Infect. Drug Resist."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.2147\/IDR.S535755","article-title":"Shifts in Epidemiology and Antibiotic Resistance of Haemophilus Influenzae in Children From Chongqing (2019\u20132024): Pre-, During, and Post-COVID-19","volume":"18","author":"Wang","year":"2025","journal-title":"Infect. Drug Resist."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e00968-19","DOI":"10.1128\/JCM.00968-19","article-title":"Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program","volume":"57","author":"Waites","year":"2019","journal-title":"J. Clin. Microbiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3345\/kjp.2017.60.6.167","article-title":"Mechanism of Resistance Acquisition and Treatment of Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Children","volume":"60","author":"Yang","year":"2017","journal-title":"Korean J. Pediatr."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3892\/etm.2024.12713","article-title":"Atypical Pneumonia (Review)","volume":"28","author":"Georgakopoulou","year":"2024","journal-title":"Exp. Ther. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/14656566.2015.999041","article-title":"Treatment of Chlamydial Infections: 2014 Update","volume":"16","author":"Kohlhoff","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Pappa, O., Chochlakis, D., Sandalakis, V., Dioli, C., Psaroulaki, A., and Mavridou, A. (2020). Antibiotic Resistance of Legionella pneumophila in Clinical and Water Isolates-A Systematic Review. Int. J. Environ. Res. Public. Health, 17.","DOI":"10.3390\/ijerph17165809"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Tewolde, R., Thombre, R., Farley, C., Nadarajah, S., Khan, I., Sewell, M., Spiller, O.B., and Afshar, B. (2025). Comparison of Phenotypic and Whole-Genome Sequencing-Derived Antimicrobial Resistance Profiles of Legionella pneumophila Isolated in England and Wales from 2020 to 2023. Antibiotics, 14.","DOI":"10.3390\/antibiotics14101053"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Coombs, G.W., Yee, N.W.T., Daley, D., Bennett, C.M., Robinson, J.O., Stegger, M., Shoby, P., and Mowlaboccus, S. (2022). Molecular Epidemiology of Penicillin-Susceptible Staphylococcus aureus Bacteremia in Australia and Reliability of Diagnostic Phenotypic Susceptibility Methods to Detect Penicillin Susceptibility. Microorganisms, 10.","DOI":"10.3390\/microorganisms10081650"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"El Mammery, A., Ram\u00edrez de Arellano, E., Ca\u00f1ada-Garc\u00eda, J.E., Cercenado, E., Villar-G\u00f3mara, L., Casquero-Garc\u00eda, V., Garc\u00eda-Cobos, S., Lepe, J.A., Ruiz de Gopegui Bordes, E., and Calvo-Montes, J. (2023). An Increase in Erythromycin Resistance in Methicillin-Susceptible Staphylococcus aureus from Blood Correlates with the Use of Macrolide\/Lincosamide\/Streptogramin Antibiotics. EARS-Net Spain (2004\u20132020). Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1220286"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Jama-Kmiecik, A., M\u0105czy\u0144ska, B., Frej-M\u0105drzak, M., Choroszy-Kr\u00f3l, I., Dudek-Wicher, R., Pi\u0105tek, D., Kujawa, K., and Sarowska, J. (2025). The Changes in the Antibiotic Resistance of Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis and Enterococcus faecium in the Clinical Isolates of a Multiprofile Hospital over 6 Years (2017\u20132022). J. Clin. Med., 14.","DOI":"10.3390\/jcm14020332"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/1\/58\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T14:05:16Z","timestamp":1767621916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/1\/58"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["antibiotics15010058"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15010058","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}